SCHEMBL29386355

SCHEMBL29386355

O=C1CCC2(CC1)C(=O)Nc1ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.60
OPRM1 P35372 1/20 0.51
OPRK1 P41145 1/20 0.51
OPRL1 P41146 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
CYP2C9 P11712 1/20 0.50
PDK2 Q15119 1/20 0.48
PDK4 Q16654 1/20 0.48
HTR1A P08908 6/20 0.47
HTR2A P28223 6/20 0.47
HTR7 P34969 6/20 0.47
HTR6 P50406 6/20 0.47
TNKS O95271 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924203 1.00 BACE1 (0.60) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL29622026 0.88 BACE1 (0.68) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL318668 0.88 BACE1 (0.68) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL29387092 0.85 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL1268479 0.85 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL29609089 0.85 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL2265580 0.85 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL29799132 0.83 BACE1 (0.62) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL21537944 0.83 BACE1 (0.62) BACE1OPRM1OPRK1OPRL1MEN1
SCHEMBL1223213 0.83 BACE1 (0.62) BACE1OPRM1OPRK1OPRL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076632-A1 COMPOUNDS AND USES THEREOF FIBROCOR THERAPEUTICS INC. (CA) 2025-04-17 WO disclosed
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-12-05 US disclosed
CN-116940552-A Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2023-10-24 CN disclosed
EP-4192957-A2 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2023-06-14 EP disclosed
CN-116113698-A TRPML modulators 卡斯玛治疗公司 2023-05-12 CN disclosed
CN-109996792-B Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain 赫普泰雅治疗有限公司 2023-02-17 CN disclosed
US-20220213034-A1 SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-07-07 US disclosed
WO-2022032073-A2 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213034-A1 SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM4 BACE1 570/4885OPRM1 27/4885OPRK1 78/4885
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists CHRM1, CHRM2, CHRM4 BACE1 570/4885OPRM1 27/4885OPRK1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.